Cancer News and Research

Latest Cancer News and Research

CTRC-AACR San Antonio Breast Cancer Symposium presents new data on emerging breast cancer therapies

Breast cancer continues to be a dynamic field of research, and the CTRC-AACR San Antonio Breast Cancer Symposium, now in its 32nd year, is the premier destination to present new data on emerging therapies.

14 Dec 2009

Breast Cancer Fund: It's time for the FDA to issue immediate ban on BPA in hard plastic food containers

It's been almost two weeks since the Food and Drug Administration missed its deadline to announce the results of a new safety assessment of the toxic plastics chemical bisphenol A, or BPA, and each day more newborn babies and pregnant women are left unprotected from this hormone-disrupting compound linked to breast cancer and birth defects.

14 Dec 2009

Preclinical graft study supports Cytori’s proposed mechanism of action

Cytori Therapeutics reported results from a preclinical cell-enriched fat grafting study supporting the safety and efficacy of Cytori’s method for enriching fat grafts with adipose-derived regenerative cells (ADRCs).

14 Dec 2009

International experts prepare check-list for identifying insulin and cancer risk

Epidemiological studies are difficult to do well, pharmacoepidemiological studies are particularly complicated and studies of insulin and cancer risk are even more difficult to do well. "Well" in the sense that any association found can be interpreted in an unambiguous manner.

14 Dec 2009

Researchers present new data for diagnosis and management of beast cancer

As therapies for breast cancer continue to emerge, the issues of how to best monitor success and gauge prognosis remain important questions.

14 Dec 2009

Myrrh resin may have cholesterol-lowering properties

Laboratory experiments suggest that the resin of certain trees of the Middle East, known commonly as the "myrrh" of the Christmas story, may have cholesterol-lowering properties.

14 Dec 2009

Study finds racial disparities in breast cancer care

Black women are less likely than white women to receive radiation therapy after a lumpectomy, the standard of care for early stage breast cancer, according to a new study by researchers at The University of Texas M. D. Anderson Cancer Center.

14 Dec 2009

Approval of injectable formulation using NanoCrystal technology announced

Elan Drug Technologies, a business unit of Elan Corporation, plc announces the approval by the Japanese Ministry of Health, Labour and Welfare of EMEND® (aprepitant) for the treatment of cancer chemotherapy-induced nausea and vomiting.

14 Dec 2009

Diabetic patients exposed to insulin glargine have higher incidence of cancer, shows study

Type 2 diabetes and obesity are linked to an increased risk of certain cancers. Recently published studies suggested that insulin glargine (a synthetic insulin preparation marketed under the trade name Lantus), may be associated with a higher risk of certain cancers than other insulins or oral glucose lowering medications.

14 Dec 2009

New antibody-drug compound halts growth of metastatic breast tumors

A new antibody-drug compound shrank or halted the growth of metastatic breast tumors in almost half of a group of patients whose HER2-positive cancer had become resistant to standard therapies, according to early data from a multicenter Phase 2 clinical trial led by a Dana-Farber Cancer Institute researcher.

14 Dec 2009

Additional therapy and screening may be needed for patients with mucinous breast cancer

In a large review of breast cancer patients with mucinous carcinoma, researchers at The University of Texas M. D. Anderson Cancer Center have identified an association between this rare type of breast cancer long-associated with a favorable prognosis and multiple tumors undetected by mammography or ultrasound.

14 Dec 2009

Several DNA sequences linked to impaired pulmonary function, uncovers new study

A new study involving data from more than 20,000 individuals has uncovered several DNA sequences linked to impaired pulmonary function. The research, an analysis that combined the results of several smaller studies, provides insight into the mechanisms involved in reaching full lung capacity.

14 Dec 2009

Cell-enriched breast reconstruction procedure improves breast deformity in lumpectomy patients

Interim results from a European clinical trial, RESTORE 2, demonstrate that cell-enriched breast reconstruction achieved a high rate of patient and physician satisfaction and improvements in overall breast deformity in lumpectomy patients.

14 Dec 2009

African American women with breast cancer receive no follow-up care after lumpectomy, shows study

A new study finds many breast cancer patients - particularly African American women - do not receive recommended radiation treatments after undergoing a lumpectomy.

14 Dec 2009

Pfizer announces results from studies evaluating neratinib

Pfizer Inc. today announced results from studies evaluating neratinib (HKI-272), an investigational, orally administered, pan-ErbB inhibitor, in patients with human epidermal growth factor receptor-2 (HER2, also known as ErbB2) positive breast cancer at the 2009 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).

14 Dec 2009

Results from Phase 2 trial evaluating Nexavar with capecitabine and paclitaxel presented

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced results from two collaborative group-sponsored randomized, double-blind, placebo-controlled Phase 2 trials were presented at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS).

14 Dec 2009

Tulane Cancer Center starts randomizing patients in phase III clinical study of Alpharadin

Algeta ASA, the cancer therapeutics company, announces that the first clinical center in the US, the Tulane Cancer Center, New Orleans, has started randomizing patients in the phase III clinical study of Alpharadin in men with castration-resistant (also known as hormone-refractory) prostate cancer (CRPC) that has metastasized to the skeleton.

14 Dec 2009

Combination therapy improves overall survival in women with advanced breast cancer

In a clinical study, women with an aggressive form of breast cancer experienced a median survival of 14 months when treated with an investigational combination of TYKERB® (lapatinib) plus HERCEPTIN® (trastuzumab). The results of the Phase III study in HER2-positive metastatic breast cancer were presented during the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held in San Antonio, Texas (Dec. 9 - 13).

14 Dec 2009

Black women with HR-positive breast cancer have worse disease-free and overall survival, shows data

Black women with hormone receptor (HR)-positive breast cancer had worse disease-free and overall survival, according to data presented at the CTRC-AACR Annual San Antonio Breast Cancer Symposium, held Dec. 9-13, 2009.

14 Dec 2009

Ipsen announces preliminary results of phase I trial in metastatic breast cancer with BN83495

Ipsen today announced the preliminary results of a phase I trial in metastatic breast cancer with BN83495, Ipsen’s lead and first-in-class orally available irreversible steroid sulfatase (STS) inhibitor.

14 Dec 2009

Cancer News and Research

Latest Cancer News and Research

CTRC-AACR San Antonio Breast Cancer Symposium presents new data on emerging breast cancer therapies

Breast Cancer Fund: It's time for the FDA to issue immediate ban on BPA in hard plastic food containers

Preclinical graft study supports Cytori’s proposed mechanism of action

International experts prepare check-list for identifying insulin and cancer risk

Researchers present new data for diagnosis and management of beast cancer

Myrrh resin may have cholesterol-lowering properties

Study finds racial disparities in breast cancer care

Approval of injectable formulation using NanoCrystal technology announced

Diabetic patients exposed to insulin glargine have higher incidence of cancer, shows study

New antibody-drug compound halts growth of metastatic breast tumors

Additional therapy and screening may be needed for patients with mucinous breast cancer

Several DNA sequences linked to impaired pulmonary function, uncovers new study

Cell-enriched breast reconstruction procedure improves breast deformity in lumpectomy patients

African American women with breast cancer receive no follow-up care after lumpectomy, shows study

Pfizer announces results from studies evaluating neratinib

Results from Phase 2 trial evaluating Nexavar with capecitabine and paclitaxel presented

Tulane Cancer Center starts randomizing patients in phase III clinical study of Alpharadin

Combination therapy improves overall survival in women with advanced breast cancer

Black women with HR-positive breast cancer have worse disease-free and overall survival, shows data

Ipsen announces preliminary results of phase I trial in metastatic breast cancer with BN83495

Understanding the DNA Damage Response in Innate Immunity eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in